On August 29, 2024 Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA gene therapies, reported its first half-year 2024 results (Press release, Circio, AUG 29, 2024, View Source [SID1234646152]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Circio’s management will present the results in a live-streamed webcast at 10:00 am CEST to investors, analysts and the press. Click here for access to the live webcast
Questions can be submitted by email in advance (to: [email protected]) and during the presentation.
Reporting material attached to this press release:
Circio first-half year report 2024
Circio 1H24 webcast presentation
The report and presentation are also available at www.circio.com
First half-year 2024 highlights
Corporate
In January, Business Finland approved Circio’s application for a waiver of three R&D loans totaling NOK 71.3 million
In May, launched a financing transaction securing cash runway for 12 months through a rights issue and parallel commitment from Atlas Capital Markets
Cash burn of NOK 19 million, representing a 68% reduction versus 1H23
Circular RNA
In April, announced technical in vivo proof-of-concept for its proprietary circVec circular RNA platform with >4-month expression durability
In May, presented two circVec posters at the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 2024 annual meeting in Baltimore, USA
In June, announced a new generation circVec 2.2, achieving 2-4-fold higher expression than v2.1 and up to 15x improvement over mRNA expression
Mutant KRAS
In February, announced that the first patient was dosed in the Georgetown University Phase 2 study, testing TG01 in a triple combination in collaboration with Janssen and BMS
In March, the Chinese National Medical Products Administration (NMPA) approved the investigational new drug (IND) application of TG01